WARN : Please note that some of the values may not be in base currency

Fundamental Analysis of Immunoprecise Antibodies Ltd - Growth / Value Index


IPA - Valuation Highlights

Valuation Analysis

   Price to Book Ratio is 0.533 indicating that it is undervalued.
   Tsr Value Index - Poor Score of 21.88
   Book Value in last 3 years is trending down
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning -2.10 -1.10 4.78 %
Price to Book 0.529 0.505 97.14 % 0.563
Price to Sales 1.24 1.41 41.83 %
Enterprise Value to EBITDA Multiple -2.68 -1.04 -242.19 %


IPA - Profitability Highlights

Profitability Analysis

   Company's Net Profit is increasing for last 5 Quarters
   Company's Profit Before Tax is increasing for last 5 Quarters
   Steady Growth in EPS for last four quarters
   Tsr Profitability Index - Very Poor Score of 5.00
   Piotroski F Score - Very Poor Value of 2.0
   Very Low Dividend Yield of 0 %
   Negative Net profit for last two years
   Company Net profit is Negative for last 5 Quarters
   In the last three years, the company has given poor Net Margin
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
   Negative Net Margin MRQ
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity -25.18 -45.95 -107.03 % -5.04
Return On Asset -17.96 -34.13 -90.99 % -3.47
Net Profit Margin -59.04 -128.53 -48.95 % -42.63
Operating Profit Margin -64.95 -135.25 -61.96 % -45.43
EBITDA Margin -37.35 -102.90 -70.89 % -23.43


Highlights
Market Cap30788.90 K
Enterprise Value23624.90 K
Price/Book TTM0.529
Outstanding Share26315.30 K
Float/ Outstanding Share86.61%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No0
Peter Lynch Ratio0
Piotroski F Score2.00
Altman Z Score-1.14
Sloan Ratio-0.061
Peter Lynch Fair Value0


IPA - Growth Highlights

Growth Analysis

   YoY Net Margin Jump by 48.95%
   Annual sales of the company is increased for three years in a row
   Quarterly sales in last 5 years is trending up
   Operating Cash Flow decreasing for last 3 year
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 23609.00 K 6.72 % 0 %
Gross Profit 12044.00 K 5.28 % 0 %
EBITDA -8817.00 K 82.37 % 0 %
Net Profit -13938.00 K 58.96 % 0 %
EPS -0.557 5.02 % NA


IPA - Stability Highlights

Stability Analysis

   Debt to equity ratio has decreased and is lowest in last five years
   Decreasing debt with Increasing revenue
   Altman Z Score of -1.14 suggest high risk
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of -931.63
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0.0193 -33.99 % 0.0183
Cash Ratio 1.40 -56.76 %
Quick Ratio 2.49 -35.71 % 1.72
Shareholders Equity 74.28 -7.75 %
Debt to EBITDA -0.052 72.21 %


Historical Valuation Ratios of Immunoprecise Antibodies Ltd

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Immunoprecise Antibodies Ltd

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Immunoprecise Antibodies Ltd

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Immunoprecise Antibodies Ltd

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)